A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies.

Principal Investigator

Dr Graham Collins

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1004077